Association of Norepinephrine Transporter Gene and Side Effects of Osmotic-Release Oral System Methylphenidate in Attention-Deficit Hyperactivity Disorder.
10.5765/jkacap.2014.25.2.82
- Author:
Jungeun SONG
1
;
Hyun Ju HONG
;
Byung Ook LEE
;
Ki Hwan YOOK
Author Information
1. Department of Psychiatry, National Health Insurance Service Ilsan Hospital, Goyang, Korea.
- Publication Type:Original Article
- Keywords:
ADHD;
SLC6A2;
OROS Methylphenidate;
Side Effects
- MeSH:
Child;
Genotype;
Humans;
Methylphenidate*;
Norepinephrine Plasma Membrane Transport Proteins*;
Parents;
Polymorphism, Single Nucleotide
- From:Journal of the Korean Academy of Child and Adolescent Psychiatry
2014;25(2):82-88
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
OBJECTIVES: The aim of our study was to investigate association of norepinephrine transporter gene (SLC6A2) polymorphism and side effects of osmotic-release oral system methylphenidate (OROS MPH) in children with attention-deficit hyperactivity disorder (ADHD). METHODS: We recruited drug naive children with ADHD (N=97). We administered OROS MPH by tolerable dosage. At week 8 of treatment, parents completed the Barkley's side effect rating scale. We analyzed two SLC6A2 single nucleotide polymorphisms (SNPs), rs192303 and rs3785143, with blood of subjects. We compared the frequency and severity of each side effect among SLC6A2 genotypes of 2 SNPs. RESULTS: In the analysis of frequency of each side effect, irritability differed according to rs192303 and rs3785143 genotype. In comparisons of severity, talking less and disinterest differed according to rs192303 genotype. In the case of rs3785143, severities of disinterest and irritability were involved with genotype. CONCLUSION: Side effects of OROS MPH showed an association with SLC6A2 genotype.
